Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time

First-of-its-kind technology stack in autoimmune diseases.

Provides unprecedented insights into optimal patient treatment pathway.

WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.

The acquisition gives Scipher new data management and analytics capabilities to enable a more granular and real-time understanding of patients’ treatment pathway. CrossBridge’s SaaS value-based care platform bridges gaps between patients, providers, payers, and improves health outcomes and lowers the cost of care for autoimmune disease patients. The transaction has closed, and terms were not disclosed.

There is a significant need to better understand how and when to apply various therapeutic and diagnostic interventions to improve the treatment pathway for patients,” said Scipher’s Chief Executive Officer Alif Saleh. “To date, we have not had a platform combining critical patient molecular, clinical and claims data as autoimmune diseases, including rheumatoid arthritis.

“The addition of CrossBridge will accelerate our growth and advance our mission to match each patient with their most effective therapy while creating seamless EMR integration and efficiencies for healthcare systems and payers,” added Saleh. “The acquisition allows us to collect and map clinical data and outcomes over time to better track the evolution of patient health and the value of healthcare interventions including blood-based therapy selection tests such as PrismRA.”

PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFI therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles.

“We are excited to contribute to the vital innovation that Scipher has pioneered for millions of patients, and we are glad to see our data analytics capabilities used to deliver value to patients, providers and payers,” said CrossBridge Founder Bill Conlan.

“This acquisition is an exciting milestone and a key part of our growth strategy,” Saleh said. “One of our goals is to disrupt systemic inefficiencies in healthcare, and CrossBridge will help us realize that vision.”


About Scipher

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.


Media Relations 
Corporate Communications  

Investor Relations